Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
European Society of Gynaecological Oncology (ESGO)
European Society of Gynaecological Oncology (ESGO)
The
European Society of Gynaecological Oncology
(
ESGO
) is a Europe-wide society of health care professionals and researchers specializing in the study, prevention, treatment and care of gynaecological cancers. The society, which has more than 1,000 members from over 30 European countries, was founded in Venice, Italy, in 1983.
Effect of Online Education on Clinician Knowledge of the Role of PARP Inhibitors in Newly Diagnosed Advanced Ovarian Cancer
ESGO 2020
An on-demand online video panel discussion regarding the use of PARP inhibitors in patients with newly diagnosed advanced ovarian cancer resulted in a positive educational impact among oncologists and obstetrician-gynecologists.
Read More ›
Feasibility of Personalized Ovarian Cancer Risk Prediction with Population-Based Genetic Testing
ESGO 2020
Population-based personalized ovarian cancer risk stratification is feasible and acceptable. Participants reported high satisfaction without a negative impact on psychological health or quality of life.
Read More ›
Clinical Characteristics and Prognosis of Ovarian Clear-Cell Carcinoma
ESGO 2020
The level of CA 19-9, expression of HE4, and the presence of massive ascites or positive lymph nodes are important prognostic factors for overall survival in patients with ovarian clear-cell carcinoma.
Read More ›
Feasibility of a Randomized Controlled Trial of Robotic Interval Debulking Surgery for Ovarian Cancer
ESGO 2020
In the MIRRORS study, researchers aim to determine the feasibility of a randomized controlled trial of robotic interval debulking surgery for patients with ovarian cancer. While robotic surgery is unlikely to be suitable for all cases of ovarian cancer, researchers hope that robotic surgery may provide improved quality of life and recovery in selected women.
Read More ›
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer
ESGO 2020
The efficacy and safety of treatment with niraparib was similar in older patients and in those aged 65 years. An individualized starting dose decreased the rate of thrombocytopenia adverse events in older patients.
Read More ›
Page 2 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us